Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

3 years ago

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing…

Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement

3 years ago

Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of…

Aurora Spine Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference

3 years ago

CARLSBAD, Calif. , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB:…

CorVel Launches New Workers’ Compensation and Liability Solution, Leveraging Artificial Intelligence and Predictive Analytics

3 years ago

CogencyIQ helps risk managers and claims professionals navigate increasingly complex claims and massive amounts of data to improve outcomes for…

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022

3 years ago

NEW YORK and SALT LAKE CITY, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial…

Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe

3 years ago

Advicenne announces significant progress in marketing its lead product Sibnayal™ in Europe First round of pricing negotiations completed in the…

Jushi Holdings Inc. Announces Participation in Upcoming Conferences in December 2021

3 years ago

BOCA RATON, Fla., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF),…

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC

3 years ago

Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC Series A round led by Pontifax and includes…

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

3 years ago

Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target…

MediPharm Labs Announces Changes to Board of Directors

3 years ago

BARRIE, Ontario, Dec. 07, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or…